ARHGAP42: A Potential Drug Target and Biomarker for GTPase-Activating Proteins

Target Name: ARHGAP42

NCBI ID: G143872

ARHGAP42

ARHGAP42: A Potential Drug Target and Biomarker for GTPase-Activating Proteins

Introduction

Guanosine triphosphate (GTP) is a crucial molecule in many cellular processes, including intracellular signaling, DNA replication, and protein synthesis. GTPase-activating proteins (GAPs) are enzymes that regulate the formation of GTP from nucleotides, and they play a central role in the regulation of cellular processes. The ARHGAP42 gene is a non-coding RNA molecule that has been identified as a GAP42-like protein. In this article, we will discuss the potential drug target and biomarker properties of ARHGAP42.

Structure and Function

The ARHGAP42 gene encodes a protein that has a molecular weight of approximately 42 kDa. The protein is composed of 115 amino acid residues and has a calculated pI of 6.3. The protein has a distinct N-terminal region that contains a putative nucleotide-binding domain (NBD), a conserved catalytic core, and a C-terminal region that contains a unique structural domain called the GAP-binding domain (GBD).

The NBD and GBD regions of ARHGAP42 are similar to those of other GAPs, including the catalytic domain and the nucleotide-binding motif (NBM), which are important for GAP function. The NBD region of ARHGAP42 contains a conserved nucleotide-binding motif (NBM) ) that is similar to those of other GAPs, including the catalytic domain and the NBM. The NBM is responsible for the protein's ability to bind to nucleotides and for its role in GAP function.

The GBD region of ARHGAP42 is unique and is responsible for the protein's unique structure and function. The GBD region contains a conserved nucleotide-binding motif (NBM) and a unique structural domain that is involved in the regulation of GTP formation. The NBM and GBD Region of ARHGAP42 are involved in the regulation of GTP formation and have been implicated in the regulation of cellular processes, including intracellular signaling, DNA replication, and protein synthesis.

Drug Targeting

ARHGAP42 has been identified as a potential drug target due to its unique structure and function. The NBD and GBD regions of ARHGAP42 make it a unique target for small molecules, including inhibitors of GAP function and modulators of GTP formation. Several studies have shown that inhibitors of GAP function can inhibit the activity of ARHGAP42 and disrupt its role in the regulation of cellular processes.

In addition, modulators of GTP formation, such as inhibitors of the GTPase enzyme, have also been shown to be potential drug targets for ARHGAP42. The GBD region of ARHGAP42 is involved in the regulation of GTP formation and has been shown to play a role in the regulation of intracellular signaling. Therefore, inhibitors of GTP formation that target the GBD region of ARHGAP42 may be effective in inhibiting its activity and blocking its role in cellular processes.

Biomarker

ARHGAP42 has also been identified as a potential biomarker for the treatment of various diseases, including cancer. The regulation of GTP formation by ARHGAP42 is involved in the regulation of cellular processes that are critical for the survival and growth of cancer cells. Therefore, changes in the regulation of GTP formation by ARHGAP42 may be a potential biomarker for the treatment of cancer.

ARHGAP42 has been shown to be involved in the regulation of cell proliferation, apoptosis, and angiogenesis, which are critical processes for cancer development. In addition, changes in the regulation of GTP formation by ARHGAP42 have also been implicated in the regulation of

Protein Name: Rho GTPase Activating Protein 42

Functions: May influence blood pressure by functioning as a GTPase-activating protein for RHOA in vascular smooth muscle

The "ARHGAP42 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ARHGAP42 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets